Evidence map›Paper›PMID 35727806›Full record

ArticlePloS one2022

High throughput SARS-CoV-2 variant analysis using molecular barcodes coupled with next generation sequencing.

Lyora A Cohen-Aharonov, Annie Rebibo-Sabbah, Adar Yaacov, Roy Z Granit, Merav Strauss, Raul Colodner, Ori Cheshin, Shai Rosenberg, Ronen Eavri

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lyora A Cohen-AharonovBarcode Diagnostics Ltd., Nazareth, Israel.
Annie Rebibo-SabbahBarcode Diagnostics Ltd., Nazareth, Israel.
Adar YaacovLaboratory for Computational Biology of Cancer, Sharett Institute for Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.ORCID 0000-0002-6106-2307
Roy Z GranitBarcode Diagnostics Ltd., Nazareth, Israel.
Merav StraussMicrobiology Laboratory, Emek Medical Center, Afula, Israel.
Raul ColodnerMicrobiology Laboratory, Emek Medical Center, Afula, Israel.
Ori CheshinInternal Medicine E, Emek Medical Center, Afula, Israel.
Shai RosenbergLaboratory for Computational Biology of Cancer, Sharett Institute for Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
Ronen EavriBarcode Diagnostics Ltd., Nazareth, Israel.
Emek Medical Center · ILHadassah Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of SARS-CoV-2 variants across the globe and their implications on the outspread of the pandemic, infection potential and resistance to vaccination, requires modification of the current diagnostic methods to map out viral mutations rapidly and reliably. Here, we demonstrate that integrating DNA barcoding technology, sample pooling and Next Generation Sequencing (NGS) provide an applicable solution for large-population viral screening combined with specific variant analysis. Our solution allows high throughput testing by barcoding each sample, followed by pooling of test samples using a multi-step procedure. First, patient-specific barcodes are added to the primers used in a one-step RT-PCR reaction, amplifying three different viral genes and one human housekeeping gene (as internal control). Then, samples are pooled, purified and finally, the generated sequences are read using an Illumina NGS system to identify the positive samples with a sensitivity of 82.5% and a specificity of 97.3%. Using this solution, we were able to identify six known and one unknown SARS-CoV-2 variants in a screen of 960 samples out of which 258 (27%) were positive for the virus. Thus, our diagnostic solution integrates the benefits of large population and epidemiological screening together with sensitive and specific identification of positive samples including variant analysis at a single nucleotide resolution.

Indexed as

COVID-19SARS-CoV-2High-Throughput Nucleotide SequencingHumansPandemics

Identifiers

PMID35727806
PMCPMC9212143
OpenAlexW4283207887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.